Rang & Dale's Pharmacology Flash Cards

Description

Organized in conjunction with Rang and Dale’s Pharmacology 9th edition, Rang & Dale's Pharmacology Flashcards helps you review what you learn in class and reinforce essential information. One side of each flashcard features a diagram of the pathophysiological processes including the drug class at the top of the card. The back of the card details essential information for that drug class including actions, mechanism of action, pharmacokinetic aspects, adverse effects, the names of related drugs and important aspects of clinical use. Access to this product, which may be at the discretion of your institution, is up to 3 years of online and perpetual offline access. Elsevier reserves the right to restrict or remove access due to changes in product portfolio or other market conditions. Completely updated with the latest knowledge in pharmacology and clinical use. New chapter on drugs used for eye and skin conditions, new coverage of clinical use of biopharmaceuticals in a wide range of conditions, and a concise explanation of the rapidly growing impact of pharmacogenetics. Clinical correlations help you apply information to real-life situations. Compact and efficient size make it easy to carry selected cards with you and study on the go. A perfect study aid and complement to Rang & Dale’s Pharmacology, 9th Edition–―ideal for exam preparation. Student Consult™ eBook version included with purchase. This enhanced eBook experience allows you to study the cards on your phone, tablet, or computer. Front Cover Inside Front Cover Rang and Dale’s Pharmacology Flashcards Copyright Page Table Of Contents How to Use These Cards Preface Acknowledgements Drug Index A B C D E F G H I J K L M N O P Q R S T U V W X Z Abbreviations I Cholinergic pharmacology 1.01 Muscarinics – Eye Pilocarpine, cevimeline 1.02 Antimuscarinics – Eye Atropine, tropicamide, cyclopentolate 1.03 Antimuscarinics – Gastrointestinal Hyoscine, dicycloverine, atropine, glycopyrronium 1.04 Antimuscarinics – Bladder Oxybutynin, tolterodine, trospium, solifenacin 1.05 Neuromuscular Blocker Depolarizing agent: succinylcholine (suxamethonium) 1.06 Neuromuscular Blocker Nicotinic antagonist: pancuronium, vecuronium, rocuronium, mivacurium, etc. 1.07 Peripheral Anticholinesterases Neostigmine, pyridostigmine, physostigmine 1.08 Nicotinic Partial Agonists Varenicline II Noradrenergic pharmacology 2.01 β2-Receptor Agonist Short-acting: salbutamol (albuterol), terbutaline 2.02 β1-Receptor Antagonist Selective: atenolol, bisoprolol, etc.; non-selective: propranolol; mixed α/β: labetalol, etc. 2.03 α- and β-Receptor Agonists Epinephrine (adrenaline) 2.04 α1-Receptor Antagonist Selective: prazosin, doxazosin, tamsulosin; non-selective: phenoxybenzamine 2.05 β1-Receptor Agonist Dobutamine 2.06 α1-Receptor Agonist Phenylephrine, xylometazoline, etc. 2.07 Drugs That Release Noradrenaline Amfetamine, methylphenidate, atomoxetine 2.08 Selective β3- Adrenoceptor Agonist Mirabegron 2.09 α2-Agonist Prodrug Methyldopa 2.10 DOPA Decarboxylase Inhibitor Carbidopa, benserazide III Inflammation and anti-inflammatory drugs 3.01 NSAIDs Ibuprofen 3.02 NSAIDs Aspirin 3.03 NSAIDs Paracetamol 3.04 COX-2 Inhibitors Celecoxib, etoricoxib, parecoxib 3.05 DMARDs Immunosuppressive disease-modifying anti-rheumatoid drug: methotrexate 3.06 DMARDs Immunosuppressive disease-modifying anti-rheumatoid drug: sulfasalazine 3.07 DMARDs Immunosuppressive disease-modifying anti-rheumatoid drug: leflunomide 3.08 Uricosuric Agents Allopurinol, febuxostat 3.09 Antigout: Colchicine Notes Inflammation and anti-inflammatory drugs IV Drugs affecting the immune response 4.01 Calcineurin Inhibitors Immunosuppressants: ciclosporin, tacrolimus, pimecrolimus 4.02 Antiproliferative Immunosuppressant Azathioprine 4.03 Antiproliferative Immunosuppressant Mycophenolate mofetil 4.04 Antiproliferative Antibiotic Sirolimus (rapamycin) 4.05 Glucocorticoids Prednisolone, dexamethasone, hydrocortisone, triamcinolone 4.06 TNF Inhibitors Infliximab, adalimumab, etanercept, golimumab 4.07 Antibodies Against CD20 Rituximab, ofatumumab, ocrelizumab 4.08 Monoclonal Antibodies (non-CD20) Alemtuzumab, brentuximab, belimumab, vedolizumab, etc. 4.09 Interleukin Inhibitors Anakinra, tocilizumab, secukinumab, ustekinumab 4.10 JAK Monoclonal antibodies targeting JAK: Tofacitinib, baricitinib 4.11 Non-Sedating Antihistamines Cetirizine, loratadine, fexofenadine, azelastine 4.12 Sedating Antihistamine Promethazine, cyclizine, cinnarizine, chlorphenamine, etc. 4.13 Drugs Affecting the Immune Response What antihistamines are used for motion sickness? V Antidysrhythmic drugs 5.01 Class Ia Antidysrhythmic Disopyramide (similar: quinidine, procainamide) 5.02 Class Ic Antidysrhythmic Flecainide (similar: propafenone, encainide) 5.03 Class II Antidysrhythmic β-adrenoceptor antagonist (bisoprolol, esmolol, propanolol, etc.) 5.04 Class III Antidysrhythmic Amiodarone (similar: sotalol, dronedarone, ibutilide) 5.05 Class IV Antidysrhythmic Verapamil (similar: diltiazem) 5.06 Adenosine Receptor Agonists Adenosine (similar: regadenoson) 5.07 Cardiac Glycoside Digoxin IV The vascular system 6.01 ACE Inhibitors Captopril, enalapril, lisinopril 6.02 Angiotensin Antagonists Losartan, valsartan, candesartan, irbesartan 6.03 Calcium Channel Blockers Amlodipine, nifedipine, verapamil, diltiazem 6.04 Potassium Channel Activator Minoxidil 6.05 Hydralazine Vasodilator and smooth muscle relaxant 6.06 Endothelin Antagonist Bosentan VII The heart 7.01 Nitrates Glyceryl trinitrate, isosorbide mononitrate 7.02 Ivabradine Sinus node If channel inhibitor 7.03 Ranolazine Late sodium current blocker VIII Drugs for eye and skin conditions 8.01 Glaucoma Eyedrops Notes Drugs for eye and skin conditions 8.02 VEGF Inhibitors Ranibizumab, aflibercept, bevacizumab Notes Drugs for eye and skin conditions 8.03 Retinoids Vitamin A derivatives: isotretinoin, adapalene, acitretin, tretinoin 8.04 Treatment of Psoriasis Notes Drugs for eye and skin conditions 8.05 Skin Parasites Notes Drugs for eye and skin conditions IX Atherosclerosis and lipoprotein metabolism 9.01 HMG-CoA Reductase Inhibitors Statins: simvastatin, atorvastatin, pravastatin, lovastatin 9.02 Fibrates Gemfibrozil, bezafibrate, ciprofibrate, fenofibrate, clofibrate 9.03 PCSK9 Inhibitors Evolocumab, alirocumab 9.04 Cholesterol-Absorption Inhibitors Ezetimibe 9.05 Cholesterol-Absorption Inhibitors Colestyramine, colestipol, colesevelam X Haemostasis and thrombosis 10.01 Irreversible COX-1 Inhibitor Aspirin 10.02 Adenosine (P2Y12) Antagonists Clopidogrel, prasugrel, ticagrelor 10.03 GPIIb/IIIa Receptor Antagonists Abciximab, tirofiban, eptifibatide 10.04 Other Antiplatelets Drugs Dipyridamole, epoprostenol 10.05 Plasminogen Activators Alteplase, duteplase, reteplase, streptokinase 10.06 Plasminogen Inhibitor Tranexamic acid 10.07 Anticoagulants Heparin 10.08 Anticoagulants Low molecular-weight heparin: enoxaparin, dalteparin, bemiparin 10.09 Anticoagulants Vitamin K antagonist: warfarin 10.10 Direct Oral Anticoagulants Dabigatran, apixaban, rivaroxaban XI Haemopoietic system and treatment of anaemia 11.01 Haematinic Agents Folic acid 11.02 Haematinic Agents Hydroxocobalamin (a vitamin B12 haematinic preparation) 11.03 Haematinic Agents Ferrous sulfate, ferrous fumarate, ferrous gluconate 11.04 Haemopoietic Growth Factors Epoetin, darbepoetin 11.05 Haemopoietic Growth Factors Filgrastim, lenograstim, pegfilgrastim XII Respiratory system 12.01 β2-Receptor Agonists Long-acting: salmeterol, formoterol, etc. 12.02 Xanthines Theophylline (similar: roflumilast, aminophylline = theophylline ethylenediamine) 12.03 Leukotriene Antagonists Montelukast (similar: zafirlukast) 12.04 Inhaled Muscarinic Antagonists Short-acting: ipratropium; long-acting: tiotropium, aclidinium, umeclidinium, glycopyrronium 12.05 Inhaled Glucocorticoids Beclometasone, budesonide, fluticasone, etc. 12.06 Inhibitor of Mast Cells Omalizumab 12.07 Inhibition of Interleukin-5 Monoclonal antibodies: mepolizumab, reslizumab 12.08 Anti-Fibrotic Agents Drugs for idiopathic pulmonary fibrosis: pirfenidone, nintedanib Notes Respiratory system XIII Kidney 13.01 Loop Diuretics Furosemide, bumetanide 13.02 Thiazide Diuretics Hydrochlorothiazide, bendroflumethiazide, chlortalidone 13.03 Potassium-Sparing Diuretics Spironolactone, amiloride, eplerenone, triamterene 13.04 Osmotic Diuretic Mannitol XIV Gastrointestinal tract drugs 14.01 H2 Antagonist Ranitidine, famotidine, cimetidine, nizatidine 14.02 Proton Pump Inhibitors Omeprazole, lansoprazole, pantoprazole, rabeprazole, esomeprazole 14.03 Mucosal Protectants Sucralfate, bismuth subsalicylate, tripotassium dicitratobismuthate 14.04 Antacids Aluminium or magnesium hydroxide, sodium bicarbonate, calcium carbonate 14.05 Prostaglandin E Agonist Misoprostol 14.06 5-HT3 Antagonists – Antiemetics Ondansetron, granisetron, dolasetron, tropisetron 14.07 Other Antiemetics Anticholinergics, antihistamines, glucocorticoids, NK1 antagonists, cannabinoids 14.08 Osmotic Laxatives Lactulose, macrogols, magnesium sulfate 14.09 Bulk Laxatives Methylcellulose, ispaghula husk, sterculia, bran 14.10 Stimulant Laxatives Bisacodyl, senna, glycerol 14.11 Faecal Softeners Docusate, liquid paraffin, arachis oil 14.12 Other Drugs for Constipation Prucalopride, lubiprostone, linaclotide, naloxegol 14.13 Antidiarrhoeal Agent Loperamide (similar: diphenoxylate, codeine) 14.14 Other Drugs That Reduce GI Motility Eluxadoline, racecadotril XV The control of blood glucose and drug treatment of diabetes mellitus 15.01 Insulin Human recombinant insulin (or analogues) 15.02 Sulfonylureas Gliclazide, tolbutamide, glipizide, glimepiride, glibenclamide 15.03 Biguanides Metformin 15.04 Meglitinides Repaglinide, nateglinide 15.05 Glucagon-Like Peptide-1 Agonists Exenatide, liraglutide, lixisenatide, dulaglutide, albliglutide 15.06 Dipeptidyl Peptidase Inhibitors Sitagliptin, saxagliptin, vildagliptin, linagliptin, alogliptin 15.07 SGLT-2 Inhibitors Canagliflozin, dapagliflozin, empagliflozin 15.08 α-Glucosidase Inhibitors Acarbose, miglitol 15.09 Glucagon Human recombinant glucagon XVI The pituitary and the adrenal cortex 16.01 Hypothalamic Hormones Somatostatin analogues: octreotide, lanreotide, pasireotide 16.02 Hypothalamic Hormones GnRH analogues: buserelin, leuprorelin, gonadorelin 16.03 Anterior Pituitary Hormones Prolactin inhibitors: bromocriptine, cabergoline, quinagolide 16.04 Posterior Pituitary Hormones Vasopressin and analogues: desmopressin, vasopressin, terlipressin 16.05 Mineralocorticoid Fludrocortisone XVII The thyroid 17.01 Thyroid Hormone Suppression Carbimazole, propylthiouracil 17.02 Thyroid Hormone Replacement Levothyroxine (synthetic T4); similar: liothyronine (T3) XVIII Bone metabolism 18.01 Antiresorptive Drugs Bisphosphonates: alendronate, zoledronate, pamidronate, risedronate 18.02 Antiresorptive Drugs Selective oestrogen receptor modulators (SERMs): raloxifene 18.03 Antiresorptive Drugs Calcitonin 18.04 Antiresorptive Drugs Monoclonal antibody: denosumab 18.05 Anabolic Agents Recombinant form of parathyroid hormone: teriparatide 18.06 Vitamin D Preparations Ergocalciferol, alfacalcidol, calcitrol XIX Reproductive system 19.01 Oestrogens and Anti-Oestrogens Natural and synthetic oestrogens, raloxifene; anti-oestrogens: clomifene, tamoxifen 19.02 Progestogens and Anti-Progestogens Progestogens: medroxyprogesterone, norethisterone, desogestrel, cyproterone; anti-progestogens: mifepristone 19.03 Combined Oral Contraceptive Pill Oestrogen and a progestogen: ethinylestradiol + norethisterone; ethinylestradiol + desogestrel 19.04 Gonadotrophins GnRH analogues (gonadorelin, leuprorelin) and inhibitors (danazol) 19.05 Uterine Stimulants Oxytocin 19.06 Uterine Stimulants Ergometrine 19.07 Uterine Stimulants Analogues of prostaglandins E and F: carboprost, dinoprostone, misoprostol, gemeprost 19.08 Oxytocin Antagonist Atosiban 19.09 Male Sex Hormone Testosterone 19.10 Anti-Androgens 5α-reductase inhibitors (finasteride, dutasteride) and androgen antagonists (flutamide, bicalutamide, etc) 19.11 Phosphodiesterase Type V Inhibitors Sildenafil, tadalafil, vardenafil XX Neurodegenerative disorders 20.01 Drugs Used in Parkinson’s Disease Levodopa (co-beneldopa, co-careldopa) 20.02 Drugs Used in Parkinson’s Disease Dopamine agonists: pramipexole, ropinirole, rotigotine, pergolide, apomorphine 20.03 Drugs Used in Parkinson’s Disease Catechol-O-methyl transferase (COMT) inhibitors: entacapone, tolcapone 20.04 Drugs Used in Parkinson’s Disease Monoamine oxidase (MAOB) inhibitors: selegiline, rasagiline 20.05 Drugs Used in Parkinson’s Disease Antiviral agent: amantadine 20.06 Drugs Used in Parkinson’s Disease Centrally acting muscarinic antagonists: benztropine, trihexyphenidyl, orphenadrine, procyclidine 20.07 Drugs Used in Alzheimer’s Disease Cholinesterase inhibitors: donepezil, rivastigmine, galantamine 20.08 Drugs Used in Alzheimer’s Disease N-methyl-D-aspartate (NMDA) receptor antagonist: memantine 20.09 Drugs Used in Multiple Sclerosis Notes Neurodegenerative disorders XXI General anaesthetics 21.01 Inhalational Agents Volatile agents: isoflurane, desflurane, sevoflurane, halothane 21.02 Inhalational Agents Nitrous oxide 21.03 Intravenous Anaesthesia Propofol, etomidate, thiopental, ketamine XXII Anxiolytics and hypnotic drugs 22.01 Benzodiazepines Diazepam, oxazepam, nitrazepam, temazepam 22.02 Z-drugs Non-benzodiazepine agonist at benzodiazepine receptor: zolpidem, zopiclone, zaleplon 22.03 Partial Serotonin Agonist Buspirone 22.04 Other Insomnia Drugs Notes Anxiolytics and hypnotic drugs XXIII Antipsychotic drugs 23.01 First-Generation Antipsychotics Phenothiazines – chlorpromazine, fluphenazine, prochlorperazine 23.02 First-Generation Antipsychotics Butyrophenone – haloperidol 23.03 First-Generation Antipsychotics Thioxanthenes – flupentixol, zuclopentixol 23.04 Second-Generation Antipsychotics Clozapine, olanzapine 23.05 Second-Generation Antipsychotics Risperidone 23.06 Second-Generation Antipsychotics Quetiapine 23.07 Second-Generation Antipsychotics Aripiprazole 23.08 Second-Generation Antipsychotics Amisulpride, sulpiride XXIV Antidepressant drugs 24.01 Tricyclics Amitriptyline, imipramine, desipramine, clomipramine, nortriptyline 24.02 SSRIs Fluoxetine, paroxetine, citalopram, escitalopram, sertraline, fluvoxamine 24.03 SNRIs Venlafaxine, duloxetine, desvenlafaxine 24.04 Noradrenaline Reuptake Inhibitor Reboxetine, maprotiline 24.05 Monoamine Oxidase Inhibitors Phenelzine, isocarboxazid, moclobemide 24.06 α-Adrenoceptor & 5-HT Receptor Antagonist Mirtazapine 24.07 Dopamine Reuptake Inhibitor Bupropion 24.08 Drugs for Bipolar Disorder Lithium – group 1 metallic element 24.09 Drugs for Bipolar Disorder Notes Antidepressant drugs XXV Antiepileptic drugs 25.01 Sodium Channel Inhibitors Carbamazepine, oxcarbazepine, phenytoin 25.02 T-Type Calcium Channel Blockers Ethosuximide 25.03 Broad-Spectrum Antiepileptic Valproate 25.04 Benzodiazepines Lorazepam, midazolam, diazepam, clonazepam, clobazam 25.05 Barbiturates Phenobarbital 25.06 Broad-Spectrum Antiepileptic Gabapentin (similar: pregabalin) 25.07 Broad-Spectrum Antiepileptic Lamotrigine 25.08 AMPA Receptor Blockers Topiramate (similar: perampanel) 25.09 Broad-Spectrum Antiepileptic Levetiracetam (similar: brivaracetam) 25.10 Other Anticonvulsants Other antiepileptic and anti-spasticity drugs XXVI Analgesic drugs 26.01 Opioid Drugs Opioid agonists – morphine, diamorphine (heroin), buprenorphine, codeine, oxycodone 26.02 Opioid Drugs Synthetic analogues – pethidine, fentanyl, remifentanil, sufentanil 26.03 Opioid Drugs Long-acting µ opioid receptor agonist – methadone 26.04 Opioid Drugs Atypical narcotic analgesic – tramadol, tapentadol 26.05 Drugs Used for Neuropathic Pain Tricyclic antidepressants – amitriptyline nortriptyline, desipramine 26.06 Drugs Used for Neuropathic Pain Antiepileptic drugs – gabapentin, pregabalin 26.07 Drugs Used for Neuropathic Pain Antiepileptic drugs – carbamazepine 26.08 Other Analgesic Drugs Notes Analgesic drugs XXVII Psychoactive drugs 27.01 Psychomotor Stimulants Amfetamine, methylenedioxymethamfetamine (MDMA), methylphenidate 27.02 Psychomotor Stimulants Methylxanthines – caffeine, theophylline 27.03 Psychomotor Stimulants Nicotine 27.04 CNS Depressants Ethanol 27.05 Other Psychoactive Drugs Notes Psychoactive drugs 27.06 Major Psychedelic Drugs LSD, mescaline, psilocybin, salvinorin A XXVIII Local anaesthetics 28.01 Rapid-Onset LAs Lidocaine, mepivacaine, articaine 28.02 Slow- and Medium-Onset LAs Bupivacaine, levobupivacaine, ropivacaine 28.03 Topical LA Benzocaine, tetracaine, lidocaine/prilocaine combination XXIX Antibacterial drugs 29.01 Beta-Lactam Antibiotics Penicillins 29.02 Beta-Lactam Antibiotics Cephalosporins and cephamycins – ceftriaxone, cefotaxime, cefuroxime 29.03 Beta-Lactam Antibiotics Carbapenems – imipenem, meropenem, ertapenem 29.04 Blockers of Peptidoglycan Synthesis Glycopeptides – vancomycin, teicoplanin 29.05 Bacterial Protein Synthesis Blockers Tetracyclines – doxycycline, tetracycline, oxytetracycline 29.06 Bacterial Protein Synthesis Blockers Aminoglycosides – gentamicin, streptomycin, amikacin, tobramycin, neomycin 29.07 Bacterial Protein Synthesis Blockers Amphenicols – chloramphenicol 29.08 Bacterial Protein Synthesis Blockers Macrolides – erythromycin, clarithromycin, azithroymycin 29.09 Bacterial Protein Synthesis Blockers Lincosamide – clindamycin 29.10 Antibiotics Affecting Topoisomerase Quinolones – ciprofloxacin, levofloxacin, ofloxacin, norfloxacin, moxifloxacin, nalidixic acid 29.11 Blockers of Folate Synthesis/Action Sulfonamides and trimethoprim 29.12 Other Antibacterial Drugs Notes Antibacterial drugs 29.13 Antimycobacterials for Tuberculosis Notes Antibacterial drugs 29.14 Antimycobacterials for Leprosy Notes Antibacterial drugs XXX Antiviral drugs 30.01 Reverse Transcriptase Inhibitors Zidovudine 30.02 Reverse Transcriptase Inhibitors Non-nucleoside agents: nevirapine, efavirenz 30.03 Protease Inhibitors Darunavir, ritanovir 30.04 DNA Polymerase Inhibitors Aciclovir, ganciclovir 30.05 Neuraminidase Inhibitors Oseltamivir, zanamivir 30.06 Biopharmaceutical Antivirals Notes Antiviral drugs 30.07 Drugs Used in HIV Notes Antiviral drugs 30.08 Drugs Used in Hepatitis Notes Antiviral drugs XXXI Antiprotozoal drugs 31.01 Blood Schizonticides – Malaria Chloroquine, quinine, mefloquine, amodiaquine 31.02 Tissue Schizonticide – Malaria Primaquine 31.03 Folate Inhibitors – Malaria Proguanil, pyrimethamine 31.04 Artemisinin Derivatives – Malaria Artemether, artesunate, artemisinin 31.05 Treatment of Amoebiasis Amoebicides: metronidazole, tinidazole, diloxanide 31.06 Other Antiprotozoal Drugs Suramin, pentamidine, sodium stibogluconate XXXII Antifungal drugs 32.01 Antifungal Antibiotics Amphotericin, nystatin 32.02 Synthetic Antifungal Drugs – Azoles Fluconazole, itraconazole, voriconazole 32.03 Other Antifungal Drugs Griseofluvin, caspofungin, flucytosine, terbinafine, amorolfine XXXIII Mebendazole 33.01 Anthelminthic Drugs Mebendazole (similar: tiabendazole, albendazole) 33.02 Anthelminthic Drugs Levamisole 33.03 Anthelminthic Drugs Piperazine 33.04 Anthelminthic Drugs Praziquantel 33.05 Anthelminthic Drugs Ivermectin 33.06 Anthelminthic Drugs Diethylcarbamazepine 33.07 Anthelminthic Drugs Niclosamide XXXIV Anticancer drugs 34.01 Alkylating Agents and Similar Drugs Nitrogen mustards, nitrosoureas, platinum compounds, etc. 34.02 Antimetabolites Folate antagonists, pyrimidine analogues, purine analogues 34.03 Cytotoxic Antibiotics Anthracyclines, bleomycin, dactinomycin 34.04 Plant Derivatives Taxanes, vinca alkaloids, camptothecins and others 34.05 Hormones Progestogens, GnRH analogues, somatostatin analogues, anti-oestrogens, aromatase inhibitors, anti-androgens 34.06 Protein Kinase Inhibitors Tyrosine kinase inhibitors, pan-kinase inhibitors 34.07 Monoclonal Antibodies Epidermal growth factor, immune checkpoint, vascular endothelial growth factor inhibitors 34.08 Anticancer Drugs The main adverse effects of anticancer drugs XXXV General principles 35.01 Agonists and Antagonists General principles 35.02 Affinity General principles 35.03 Efficacy General principles 35.04 Competitive Antagonism General principles XXXVI Genetic variation and personalized medicine 36.01 Drug Efficacy Drugs where treatment benefit is influenced by genetic variation 36.02 Drug Safety Adverse drug reactions and genetic variation 36.03 Pharmacokinetics Genetic influences on drug metabolism and elimination XXXVII Absorption and distribution of drugs 37.01 Lipid Solubility and Ionization Absorption and distribution of drugs 37.02 Routes of Drug Administration Absorption and distribution of drugs 37.03 Bioavailability Absorption and distribution of drugs 37.04 Measurement of Bioavailability Absorption and distribution of drugs 37.05 Non-Target Binding of Drugs Absorption and distribution of drugs 37.06 Volume of Distribution, Vd Absorption and distribution of drugs XXXVIII Drug metabolism and excretion 38.01 Phase I and Phase II Metabolism Drug metabolism and excretion 38.02 Cytochrome P450 System Drug metabolism and excretion 38.03 P450 Induction and Inhibition Drug metabolism and excretion 38.04 Renal Excretion of Drugs Drug metabolism and excretion 38.05 Other Routes of Excretion Drug metabolism and excretion XXXIX Pharmacokinetics 39.01 First-Order Elimination Pharmacokinetics 39.02 Zero-Order Elimination Pharmacokinetics 39.03 Plasma Half-Life Pharmacokinetics 39.04 Clearance Pharmacokinetics